Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


DVC achieves further successful transactions and exits within its life sciences portfolio in Q1 2005


April 6th, 2005 -- Munich – DVC Deutsche Venture Capital, one of Europe’s leading venture capital companies based in Munich, achieves further successful transactions and exits within its life sciences portfolio. In the 1st quarter of 2005, the mergers of G2M Cancer Drugs AG and TopoTarget A/S as well as of Igeneon AG and Aphton Corporation have successfully been accomplished; Ardana plc has successfully completed its IPO on the London Stock Exchange (LSE) on March 4th.

Dr. Jörg Neermann, Managing Partner at DVC, remarked: „According to our approach to establish and build new biotechnoloy companies we are very pleased about further successful transactions of our portfolio companies. Following the IPO of Epigenomics AG, the first one of a biotechnology company in Germany in three years, and a substantial asset sale of Probiodrug AG to Prosidion Limited in 2004, the transactions of G2M AG, Igeneon AG and Ardana plc emphasize the competitiveness and the potential of European biotechnology companies in a global environment.”

G2M Cancer Drugs AG (G2M), Frankfurt, one of the leading German biopharmaceutical companies dedicated to the discovery of new cancer therapeutics, has in the beginning of March been acquired by the international biotechnology group TopoTarget A/S, based in Copenhagen and Oxford. With the merger, the new entity will be an important player in the field of biopharmaceutical cancer research with a worldwide leading position in the field of HDAC (Histone Deacetylase) inhibitors. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to modify activities in the cell nucleus. According to cancer experts, this class of therapeutics amounts a worldwide market volume to several billion Euro. (www.topotarget.com)

At the end of March 2005, the Nasdaq-listed biopharmaceutical company Aphton Corporation completed the 100% acquisition of Igeneon. Igeneon AG, Vienna, is a biopharmaceutical company which focuses on the development of cancer vaccines and monoclonal antibodies, two promising approaches in modern cancer therapy. Igeneon’s products are designed to prevent or delay the development of metastases in cancers of epithelial origin. The leading biotechnology company, which has been formed through the merger and is focused on immunology and cancer vaccination, will utilize the synergies to accelerate and advance the existing product pipeline as well as to establish an innovative global oncology company. (www.igeneon.com)

Ardana plc, a pharmaceutical company based in Edinburgh, has successfully completed its IPO on the London Stock Exchange (LSE) on March 4th. Since its foundation in 2000, Ardana is on its way to becoming one of the worldwide leading companies in reproductive medicine. With the IPO proceeds, Ardana will continue to invest in progressing and commercializing its product portfolio. Ardana’s first product StriantTM SR, a new testosterone replacement therapy, has been marketed in the UK since May 2004. The company intends to roll-out the sale and distribution across European-licensed territories on a country-by-country basis through local commercialization partners, starting with Germany in 2005. Other promising products, indicated for prostate cancer and benigne prostatic hyperplasia (BPH), male hypogonadism and erectile dysfunction are in advanced development stages. (www.ardana.co.uk)

DVC Deutsche Venture Capital, a leading venture capital firm based in Munich, focuses primarily on European growth companies in the areas of information, telecommunication, semiconductor and industrial technologies as well as life sciences. In the field of life sciences DVC invests in the development of therapeutic and diagnostic products as well as in platform and medical technologies. DVC’s total administrated fund volume amounts to 300 million Euro. For investments in private companies, DVC invests approximately 1 - 10 million Euro as lead inv


Publisher Contact Information:

DVC Deutsche Venture Capital
+49 (0)89 41 36 87 12
heidrun.moll@dvcg.de

Company profile of DVC Deutsche Venture Capital
Past press releases of DVC Deutsche Venture Capital.

Data


27,026
Tech investments
From our Online Data Service
17,443
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.